DNLI
Denali Therapeutics Inc. Common Stock
stockNASDAQ
denali therapeutics inc. ("denali") is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer's disease, parkinson's disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 20.98 | 2026-09-28 | -4.62% | -1.908 |
| 1M | 22.28 | 2026-09-04 | -10.19% | 1.153 |
| 3M | 25.74 | 2026-07-06 | -22.26% | 0.736 |
| 6M | 19.38 | 2026-04-06 | +3.25% | 0.801 |
| 1Y | 15.42 | 2025-10-03 | +29.77% | 1.497 |
| 2Y | 28.63 | 2024-10-04 | -30.11% | — |
| 5Y | 50.77 | 2021-10-04 | -60.59% | 1.562 |
Denali Therapeutics Inc. Common Stock (NASDAQ:DNLI) stock price today is $20.01, and today's volume is 1,629,511. DNLI is down 2.533% today. The 30 day average volume is 1.57M. DNLI market cap is $3.20B with 159.85M shares outstanding.